Tarsus Pharmaceuticals (TARS) Gross Profit (2021 - 2026)

Tarsus Pharmaceuticals' Gross Profit history runs 6 years deep, the most recent figure standing at $152.7 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 108.77% year-over-year to $152.7 million in Q1 2026; TTM through Mar 2026 was $500.2 million, a 130.2% increase from a year earlier, with the FY2025 full-year figure at $420.7 million, up 147.27% from the prior year.
• Gross Profit advanced to $152.7 million in Q1 2026 per TARS's latest filing, from $140.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $152.7 million in Q1 2026 and bottomed at $506000.0 in Q1 2022.
• The 5-year median for Gross Profit is $37.8 million (2024), against an average of $52.3 million.
• Across the five-year window, Gross Profit slumped 98.43% in 2022 and soared 2903.75% in 2024, its largest moves.
• Year by year, Gross Profit stood at $9.6 million in 2022, then gained by 23.54% to $11.9 million in 2023, then soared by 418.4% to $61.5 million in 2024, then jumped by 128.91% to $140.7 million in 2025, then rose by 8.47% to $152.7 million in 2026.
• Per Business Quant, the three latest TARS Gross Profit figures stand at $152.7 million (Q1 2026), $140.7 million (Q4 2025), and $110.4 million (Q3 2025).